These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 35484422)
1. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Alborzinia H; Flórez AF; Kreth S; Brückner LM; Yildiz U; Gartlgruber M; Odoni DI; Poschet G; Garbowicz K; Shao C; Klein C; Meier J; Zeisberger P; Nadler-Holly M; Ziehm M; Paul F; Burhenne J; Bell E; Shaikhkarami M; Würth R; Stainczyk SA; Wecht EM; Kreth J; Büttner M; Ishaque N; Schlesner M; Nicke B; Stresemann C; Llamazares-Prada M; Reiling JH; Fischer M; Amit I; Selbach M; Herrmann C; Wölfl S; Henrich KO; Höfer T; Trumpp A; Westermann F Nat Cancer; 2022 Apr; 3(4):471-485. PubMed ID: 35484422 [TBL] [Abstract][Full Text] [Related]
2. Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374 [No Abstract] [Full Text] [Related]
3. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma. Lu Y; Yang Q; Su Y; Ji Y; Li G; Yang X; Xu L; Lu Z; Dong J; Wu Y; Bei JX; Pan C; Gu X; Li B Cell Death Dis; 2021 May; 12(6):511. PubMed ID: 34011924 [TBL] [Abstract][Full Text] [Related]
4. MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in Floros KV; Chawla AT; Johnson-Berro MO; Khatri R; Stamatouli AM; Boikos SA; Dozmorov MG; Cowart LA; Faber AC Cell Stress; 2022 Feb; 6(2):21-29. PubMed ID: 35174317 [TBL] [Abstract][Full Text] [Related]
5. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma. Alborzinia H; Chen Z; Yildiz U; Freitas FP; Vogel FCE; Varga JP; Batani J; Bartenhagen C; Schmitz W; Büchel G; Michalke B; Zheng J; Meierjohann S; Girardi E; Espinet E; Flórez AF; Dos Santos AF; Aroua N; Cheytan T; Haenlin J; Schlicker L; Xavier da Silva TN; Przybylla A; Zeisberger P; Superti-Furga G; Eilers M; Conrad M; Fabiano M; Schweizer U; Fischer M; Schulze A; Trumpp A; Friedmann Angeli JP EMBO Mol Med; 2023 Aug; 15(8):e18014. PubMed ID: 37435859 [TBL] [Abstract][Full Text] [Related]
6. 4-Hydroxychalcone Induces Cell Death via Oxidative Stress in Alshangiti AM; Tuboly E; Hegarty SV; McCarthy CM; Sullivan AM; O'Keeffe GW Oxid Med Cell Longev; 2019; 2019():1670759. PubMed ID: 31885773 [TBL] [Abstract][Full Text] [Related]
7. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746 [TBL] [Abstract][Full Text] [Related]
8. Venetoclax-based Rational Combinations are Effective in Models of Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831 [TBL] [Abstract][Full Text] [Related]
9. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase. Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881 [TBL] [Abstract][Full Text] [Related]
10. Ferroptosis vulnerability in MYCN-driven neuroblastomas. Dasgupta S; Gan B Clin Transl Med; 2022 Aug; 12(8):e963. PubMed ID: 35908258 [No Abstract] [Full Text] [Related]
11. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[ Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970 [TBL] [Abstract][Full Text] [Related]
12. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration. Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367 [TBL] [Abstract][Full Text] [Related]
13. The super elongation complex drives transcriptional addiction in Wang D; Yin Z; Wang H; Wang L; Li T; Xiao R; Xie T; Han R; Dong R; Liu H; Liang K; Qing G Sci Adv; 2023 Mar; 9(13):eadf0005. PubMed ID: 36989355 [No Abstract] [Full Text] [Related]
14. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674 [No Abstract] [Full Text] [Related]
15. FOXR2 Stabilizes MYCN Protein and Identifies Non- Schmitt-Hoffner F; van Rijn S; Toprak UH; Mauermann M; Rosemann F; Heit-Mondrzyk A; Hübner JM; Camgöz A; Hartlieb S; Pfister SM; Henrich KO; Westermann F; Kool M J Clin Oncol; 2021 Oct; 39(29):3217-3228. PubMed ID: 34110923 [TBL] [Abstract][Full Text] [Related]
16. PRIMA-1 Mlakar V; Jurkovic Mlakar S; Lesne L; Marino D; Rathi KS; Maris JM; Ansari M; Gumy-Pause F J Exp Clin Cancer Res; 2019 Feb; 38(1):69. PubMed ID: 30755224 [TBL] [Abstract][Full Text] [Related]
17. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells. Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524 [TBL] [Abstract][Full Text] [Related]
18. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509 [TBL] [Abstract][Full Text] [Related]
19. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma. Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123 [TBL] [Abstract][Full Text] [Related]
20. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]